4.0 Article

Nicotine Therapy Sampling to Induce Quit Attempts Among Smokers Unmotivated to Quit A Randomized Clinical Trial

Journal

ARCHIVES OF INTERNAL MEDICINE
Volume 171, Issue 21, Pages 1901-1907

Publisher

AMER MEDICAL ASSOC
DOI: 10.1001/archinternmed.2011.492

Keywords

-

Funding

  1. National Institutes of Health
  2. Pfizer Pharmaceuticals
  3. Abbott Pharmaceuticals
  4. Aradigm
  5. American Academy of Addiction Psychiatry
  6. American Psychiatric Association
  7. American Psychiatric Institute for Research and Education
  8. Cambridge Hospital
  9. Dartmouth College
  10. Dartmouth-Hitchcock
  11. Dean Foundation
  12. DLA Piper
  13. EPI-Q
  14. European Respiratory Society
  15. Evotec
  16. Free and Clear
  17. GlaxoSmithKline
  18. Golin Harris
  19. Healthwise
  20. Integrated Communication
  21. Invivodata
  22. Maine Health
  23. McGill University Medical School
  24. McNeil Pharmaceuticals
  25. Novartis Pharmaceuticals
  26. Oglivy Health PR
  27. Ottawa Heart Institute
  28. Pinney Associates
  29. Propagate Pharmaceuticals
  30. Reckner Associates
  31. Scientia
  32. University of Arkansas for Medical Sciences
  33. University of California-San Francisco
  34. University of Wisconsin
  35. Wolters Publishing
  36. National Institute on Drug Abuse [R01DA021619, K23DA020482, K05DA000490, K12DA000357]

Ask authors/readers for more resources

Background: Rates of smoking cessation have not changed in a decade, accentuating the need for novel approaches to prompt quit attempts. Methods: Within a nationwide randomized clinical trial (N=849) to induce further quit attempts and cessation, smokers currently unmotivated to quit were randomized to a practice quit attempt (PQA) alone or to nicotine replacement therapy (hereafter referred to as nicotine therapy), sampling within the context of a PQA. Following a 6-week intervention period, participants were followed up for 6 months to assess outcomes. The PQA intervention was designed to increase motivation, confidence, and coping skills. The combination of a PQA plus nicotine therapy sampling added samples of nicotine lozenges to enhance attitudes toward pharmacotherapy and to promote the use of additional cessation resources. Primary outcomes included the incidence of any ever occurring self-defined quit attempt and 24-hour quit attempt. Secondary measures included 7-day point prevalence abstinence at any time during the study (ie, floating abstinence) and at the final follow-up assessment. Results: Compared with PQA intervention, nicotine therapy sampling was associated with a significantly higher incidence of any quit attempt (49% vs 40%; relative risk [RR], 1.2; 95% CI, 1.1-1.4) and any 24-hour quit attempt (43% vs 34%; 1.3; 1.1-1.5). Nicotine therapy sampling was marginally more likely to promote floating abstinence (19% vs 15%; RR, 1.3; 95% CI, 1.0-1.7); 6-month point prevalence abstinence rates were no different between groups (16% vs 14%; 1.2; 0.9-1.6). Conclusion: Nicotine therapy sampling during a PQA represents a novel strategy to motivate smokers to make a quit attempt.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.0
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available